Year |
Citation |
Score |
2017 |
Xiao JJ, Chen JS, Lum BL, Graham RA. A survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directions. Anti-Cancer Drugs. PMID 28542036 DOI: 10.1097/Cad.0000000000000513 |
0.313 |
|
2017 |
Abou-Alfa GK, Lewis LD, LoRusso P, Maitland M, Chandra P, Cheeti S, Colburn D, Williams S, Simmons B, Graham RA. Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment. Cancer Chemotherapy and Pharmacology. PMID 28523596 DOI: 10.1007/S00280-017-3315-8 |
0.333 |
|
2016 |
Malhi V, Colburn D, Williams SJ, Hop CE, Dresser MJ, Chandra P, Graham RA. A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib. Cancer Chemotherapy and Pharmacology. PMID 27154174 DOI: 10.1007/S00280-016-3020-Z |
0.325 |
|
2016 |
Lu D, Lu T, Stroh M, Graham RA, Agarwal P, Musib L, Li CC, Lum BL, Joshi A. A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities. Cancer Chemotherapy and Pharmacology. PMID 26811176 DOI: 10.1007/S00280-015-2931-4 |
0.332 |
|
2015 |
Rudek MA, Graham RA, Ratain MJ. Harmonization of Renal Function Assessment Is Needed During Early Clinical Development of Oncology Drugs. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26628472 DOI: 10.1200/Jco.2015.64.2553 |
0.313 |
|
2015 |
Abou-Alfa GK, Lewis LD, LoRusso P, Maitland M, Cheeti S, Colburn D, Williams S, Simmons B, Graham RA, Chandra P. Abstract CT308: Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic dysfunction: Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ct308 |
0.319 |
|
2013 |
Sharma MR, Karrison TG, Kell B, Wu K, Turcich M, Geary D, Kang SP, Takebe N, Graham RA, Maitland ML, Schilsky RL, Ratain MJ, Cohen EE. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3059-67. PMID 23553850 DOI: 10.1158/1078-0432.Ccr-12-3829 |
0.373 |
|
2013 |
Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL, Graham RA, Bray GL, Low JA. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 258-67. PMID 23082002 DOI: 10.1158/1078-0432.Ccr-12-1800 |
0.349 |
|
2013 |
LoRusso PM, Piha-Paul SA, Mita M, Colevas AD, Malhi V, Colburn D, Yin M, Low JA, Graham RA. Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential. Cancer Chemotherapy and Pharmacology. 71: 193-202. PMID 23064958 DOI: 10.1007/S00280-012-1996-6 |
0.37 |
|
2013 |
Graham RA, Cheeti S, Salphati L, Lu T, Kurkjian C, Hoff DV, Sachdev J, Juric D, Baselga J, Parmer H, Hsu J, Infante J. Abstract B218: Drug-drug interaction assessment of GDC-0032, a beta-sparing inhibitor of phosphoinositide 3-kinase (PI3K), using midazolam, a sensitive CYP3A4 substrate. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B218 |
0.411 |
|
2013 |
Juric D, Saura C, Cervantes A, Kurkjian C, Patel, Sachdev J, Mayer I, Krop I, Oliveira M, Sanabria S, Cheeti S, Lin R, Graham R, Wilson T, Parmar H, et al. Abstract PD1-3: Ph1b study of the PI3K inhibitor GDC-0032 in combination with fulvestrant in patients with hormone receptor-positive advanced breast cancer Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Pd1-3 |
0.37 |
|
2012 |
Graham RA, Hop CE, Borin MT, Lum BL, Colburn D, Chang I, Shin YG, Malhi V, Low JA, Dresser MJ. Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects. British Journal of Clinical Pharmacology. 74: 788-96. PMID 22458643 DOI: 10.1111/J.1365-2125.2012.04281.X |
0.305 |
|
2012 |
Sharma M, Kang SP, Karrison T, Wu K, Turcich M, Geary D, Takebe N, Graham RA, Maitland ML, Schilsky RL, Ratain MJ, Cohen EEW. Evaluation of food effect on pharmacokinetics (PK) of GDC-0449 (G) in advanced solid tumor patients. Journal of Clinical Oncology. 30: e13106-e13106. DOI: 10.1200/Jco.2012.30.15_Suppl.E13106 |
0.345 |
|
2011 |
Lorusso PM, Jimeno A, Dy G, Adjei A, Berlin J, Leichman L, Low JA, Colburn D, Chang I, Cheeti S, Jin JY, Graham RA. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5774-82. PMID 21753154 DOI: 10.1158/1078-0432.Ccr-11-0972 |
0.37 |
|
2011 |
Graham RA, Lum BL, Morrison G, Chang I, Jorga K, Dean B, Shin YG, Yue Q, Mulder T, Malhi V, Xie M, Low JA, Hop CE. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 1460-7. PMID 21602311 DOI: 10.1124/Dmd.111.039339 |
0.398 |
|
2011 |
Giannetti AM, Wong H, Dijkgraaf GJ, Dueber EC, Ortwine DF, Bravo BJ, Gould SE, Plise EG, Lum BL, Malhi V, Graham RA. Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449). Journal of Medicinal Chemistry. 54: 2592-601. PMID 21438527 DOI: 10.1021/Jm1008924 |
0.332 |
|
2011 |
Graham RA, Lum BL, Cheeti S, Jin JY, Jorga K, Von Hoff DD, Rudin CM, Reddy JC, Low JA, Lorusso PM. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2512-20. PMID 21300760 DOI: 10.1158/1078-0432.Ccr-10-2736 |
0.349 |
|
2011 |
LoRusso PM, Jimeno A, Dy G, Berlin J, Leichman L, Colburn D, Chang I, Cheeti S, Jin JY, Graham RA. Abstract 1310: Evaluation of optimal dosing schedule on steady-state pharmacokinetics of orally administered hedgehog pathway inhibitor GDC-0449 in cancer patients Cancer Research. 71: 1310-1310. DOI: 10.1158/1538-7445.Am2011-1310 |
0.384 |
|
2011 |
LoRusso PM, Piha-Paul SA, Colevas AD, Malhi V, Colburn D, Yin M, Low JA, Graham RA. Abstract B188: Pharmacokinetic assessment of drug-drug interaction potential when rosiglitazone or combined oral contraceptive is coadministered with vismodegib in patients with locally advanced or metastatic solid tumors. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B188 |
0.406 |
|
2010 |
Graham RA, Morrison GE, Chang I, Jorga K, Hop C, Shin Y, Malhi V, Xie M, Low JA, Lum BL. Bioavailability of the hedgehog pathway inhibitor GDC-0449 in a phase I pharmacokinetic (PK) study in healthy female subjects. Journal of Clinical Oncology. 28: e13009-e13009. DOI: 10.1200/Jco.2010.28.15_Suppl.E13009 |
0.367 |
|
2010 |
Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, Mackey HM, Graham RA, Zerivitz K, Low JA, Berlin J. Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 28: 3530-3530. DOI: 10.1200/Jco.2010.28.15_Suppl.3530 |
0.329 |
|
2010 |
Lum BL, Morrison GE, Chang I, Jorga K, Hop C, Shin Y, Malhi V, Xie M, Low JA, Graham RA. A phase I, open-label mass balance study of the hedgehog pathway inhibitor (HPI) GDC-0449 in healthy female subjects of non-childbearing potential. Journal of Clinical Oncology. 28: 2558-2558. DOI: 10.1200/Jco.2010.28.15_Suppl.2558 |
0.314 |
|
2006 |
Graham RA, Goodwin B, Merrihew RV, Krol WL, Lecluyse EL. Cloning, tissue expression, and regulation of beagle dog CYP4A genes. Toxicological Sciences : An Official Journal of the Society of Toxicology. 92: 356-67. PMID 16675513 DOI: 10.1093/Toxsci/Kfl009 |
0.56 |
|
2006 |
Graham RA, Tyler LO, Krol WL, Silver IS, Webster LO, Clark P, Chen L, Banks T, LeCluyse EL. Temporal kinetics and concentration-response relationships for induction of CYP1A, CYP2B, and CYP3A in primary cultures of beagle dog hepatocytes. Journal of Biochemical and Molecular Toxicology. 20: 69-78. PMID 16615094 DOI: 10.1002/Jbt.20118 |
0.588 |
|
2005 |
Smith CM, Graham RA, Krol WL, Silver IS, Negishi M, Wang H, Lecluyse EL. Differential UGT1A1 induction by chrysin in primary human hepatocytes and HepG2 Cells. The Journal of Pharmacology and Experimental Therapeutics. 315: 1256-64. PMID 16135700 DOI: 10.1124/Jpet.105.090795 |
0.637 |
|
2003 |
Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P, Koch P, et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 31: 421-31. PMID 12642468 DOI: 10.1124/Dmd.31.4.421 |
0.558 |
|
2002 |
Graham RA, Downey A, Mudra D, Krueger L, Carroll K, Chengelis C, Madan A, Parkinson A. In vivo and in vitro induction of cytochrome P450 enzymes in beagle dogs. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 30: 1206-13. PMID 12386126 DOI: 10.1124/Dmd.30.11.1206 |
0.412 |
|
2002 |
Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, Gilbert D, Downey A, Mudra D, Graham R, Carroll K, Xie J, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 30: 795-804. PMID 12065438 DOI: 10.1124/Dmd.30.7.795 |
0.604 |
|
Show low-probability matches. |